Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q1 2024 · 10-Q
Revenue$510.82K$510.82K−15.7% vs Q1 2023 Net Income-$1.20M-$1.20MN/M vs Q1 2023 EPS Diluted-$0.78-$0.78N/M vs Q1 2023 Operating Income-$1,268,414N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
Margins · derivedOperating margin-248.3%−97.3 pt vs Q1 2023
Net margin-234.0%−92.6 pt vs Q1 2023
ended Mar 31, 2024 · filed May 9, 2024 · 39 d after period end